Η εταιρεία Monsanto κατάφερε να κλείσει μια αποκλειστική παγκόσμια συμφωνία αδειοδότησης από το Broad Institute και το MIT του Harvard. Η συμφωνία της επιτρέπει να χρησιμοποιήσει αποκλειστικά το σύστημα επεξwork genes CRISPR. Όπως καταλαβαίνετε η εταιρεία θα το χρησιμοποιήσει για να σχεδιάσει και να αναπτύξει νέους σπconditions και φυτά. Φυσικά υπάρχουν βασικά περιορισμοί στη χρήση του CRISPR για την πρόληψη της κατάχρησης της νέας επαναστατικής technologys from Monsanto.
The financial terms of the agreement were not disclosed, but certainly this technology is not cheap. CRISPR / Cas9 technology makes it easier for geneticists to delete or add features to an organism, plant, animal, or human. 
Monsanto was bought by the German drug and drug company Bayer for 66 billion dollars last week but can not use the technology in any way it thinks fit.
Under the terms of the new agreement, the company can not carry out gene drives to "push" genetic features through a wild animal population, such as mosquitoes, weeds. An incorrect and poorly thought-out intervention in a gene could lead to unpredictable ecological consequences. That is why practice remains so controversial.
The new agreement predicts that Monsanto will not be able to use CRISPR to create seedless seeds, and many fear that the company holding the patent for this technology will choose one day to use it. By creating crops that can not self-reproduce naturally, making farmers dependent on these seeds, and in general agriculture by companies, while Monsanto makes huge profits.
Finally, Monsanto will not be able to use CRISPR on tobacco for smoking purposes.
Of course, all of this is quite worrying, just like any intervention in nature. The fact that Monsanto now belongs to Bayer Pharmaceuticals raises a number of concerns and misconceptions.
An example; Virus implantation in seeds could bring enormous profits to the pesticide industry.
